CompletedPhase 2/3

Protective Effect of N-acetylcysteine Against From Ototoxicity

Turkey (Türkiye)60 participantsStarted 2010-06

Plain-language summary

Peritonitis is currently one of the leading complications of continuous ambulatory peritoneal dialysis (CAPD). Aminoglycosides and vancomycin are used in the treatment of CAPD peritonitis despite their potential risk for ototoxicity. NAC is a molecule used in the treatment and prophylaxis of many diseases related to oxidative stress. The aim of this study was to examine whether ototoxicity due to antibiotics used in the treatment of CAPD peritonitis can be prevented by N-acetylcysteine

Who can participate

Age range18 Years – 65 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * End-stage renal disease * Undergoing continuous ambulatory peritoneal dialysis as a renal replacement therapy * Developing the first continuous ambulatory peritoneal dialysis related peritonitis episode Exclusion Criteria: * Being treated with aminoglycoside antibiotics and vancomycine within the previous 3 months * Detection of mechanical occlusion of external ear * Having signs of disturbed integrity of tympanic membrane on otoscopy or tympanometry * History of a continuous ambulatory peritoneal dialysis related peritonitis

What they're measuring

Threshold hearing levels

Timeframe: 4 weeks

Trial details

NCT IDNCT01271088

SponsorTC Erciyes University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2011-11

View on ClinicalTrials.gov More Hearing Loss, Extreme trials